Health
Molecular Partners And Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-Darpin Therapeutic Candidate MP0712 At EANM 2024
(MENAFN - GlobeNewsWire - Nasdaq) Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high ...
By: menafn
- Oct 22 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS